MCID: TRN018
MIFTS: 51

Transitional Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Transitional Cell Carcinoma

MalaCards integrated aliases for Transitional Cell Carcinoma:

Name: Transitional Cell Carcinoma 11 19 75 14 16
Carcinoma, Transitional Cell 43 71
Transitional Cell Neoplasm 11 71
Transitional Cell Carcinoma of Bladder 71
Carcinoma Transitional Cell 53
Urothelial Cell Carcinoma 11
Transitional Cell Tumor 11
Transitional Carcinoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:2671
MeSH 43 D002295
NCIt 49 C2930 C6783
SNOMED-CT 68 118287003 27090000
UMLS 71 C0007138 C0279680 C0334265

Summaries for Transitional Cell Carcinoma

GARD: 19 A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.

MalaCards based summary: Transitional Cell Carcinoma, also known as carcinoma, transitional cell, is related to bladder urothelial carcinoma and sarcomatoid transitional cell carcinoma. An important gene associated with Transitional Cell Carcinoma is UPK2 (Uroplakin 2), and among its related pathways/superpathways are DNA Damage and Endometrial cancer. The drugs Cholecalciferol and Calciferol have been mentioned in the context of this disorder. Affiliated tissues include lymph node, prostate and kidney, and related phenotypes are neoplasm and homeostasis/metabolism

Disease Ontology: 11 A carcinoma that derives from transitional epithelial cells.

Wikipedia: 75 Transitional cell carcinoma, also called urothelial carcinoma, is a type of cancer that typically occurs... more...

Related Diseases for Transitional Cell Carcinoma

Diseases related to Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 810)
# Related Disease Score Top Affiliating Genes
1 bladder urothelial carcinoma 33.4 TP53 MKI67 KRT20 FGFR3 ERBB2 CDH1
2 sarcomatoid transitional cell carcinoma 33.2 FGFR3 CDH1
3 urethra transitional cell carcinoma 33.0 UPK3A TP53 EGFR
4 papillary transitional carcinoma 32.9 UPK3A TP53 KRT7 KRT20 BRINP1
5 endometrial transitional cell carcinoma 32.9 KRT7 KRT20
6 bladder papillary transitional cell neoplasm 32.3 UPK3A TP53 KRT7 KRT20 FGFR3 BRINP1
7 fallopian tube carcinoma 32.2 TP53 MSH2 KRT7 ERBB2
8 urinary tract papillary transitional cell benign neoplasm 32.0 UPK3A TP53 KRT7 KRT20 FGFR3 BRINP1
9 prostate cancer 31.9 TP63 TP53 PTGS2 PSCA MSH2 MKI67
10 hydronephrosis 31.7 UPK3A UPK2 UPK1B KRT7
11 bladder cancer 31.6 UPK3A UPK2 UPK1A TP63 TP53 PTGS2
12 inverted papilloma 31.5 TP53 MKI67 KRT20
13 cystitis 31.5 UPK3A UPK1A TP53 PTGS2 KRT7 KRT20
14 renal cell carcinoma, nonpapillary 31.4 TP53 MKI67 KRT7 KRT20 KRT18 IFNA2
15 suppression of tumorigenicity 12 31.4 TP53 ERBB2 EGFR CDH1
16 ureteral benign neoplasm 31.3 UPK3A TP53 KRT7 KRT20 FGFR3
17 papilloma 31.3 TP63 TP53 PTGS2 KRT7 KRT20 FGFR3
18 small cell carcinoma 31.3 TP53 KRT7 KRT20 EGFR
19 urinary tract obstruction 31.2 UPK3A KRT7 CDH1
20 renal cell carcinoma, papillary, 1 31.2 TP53 KRT7 FGFR3 ERBB2 EGFR CDH1
21 appendix adenocarcinoma 31.2 TP53 KRT7 KRT20
22 papillary carcinoma 31.2 TP63 MKI67 KRT7 KRT20 ERBB2 CDH1
23 paget disease, extramammary 31.2 KRT7 KRT20 ERBB2
24 mammary paget's disease 31.1 KRT7 KRT20 ERBB2
25 serous cystadenocarcinoma 31.1 TP53 MSH2 KRT7 ERBB2 CDH1
26 nephrogenic adenoma 31.1 UPK3A KRT7
27 vesicoureteral reflux 31.1 UPK3A UPK2 UPK1B UPK1A
28 carcinosarcoma 31.0 TP53 KRT7 ERBB2 EGFR CDH1
29 squamous cell carcinoma 31.0 TP63 TP53 PTGS2 MKI67 KRT7 FGFR3
30 ureter, cancer of 31.0 MSH2 KRT7 FGFR3
31 human papillomavirus infectious disease 31.0 TP53 ERBB2 EGFR
32 vaginal cancer 31.0 TP53 KRT7 EGFR
33 adenocarcinoma 31.0 TP53 PTGS2 MSH2 KRT7 KRT20 FGFR3
34 small cell cancer of the lung 30.9 TP53 KRT7 KRT20 KRT18 EGFR
35 diarrhea 30.9 IFNA2 ERBB2 EGFR CDH1
36 colon adenocarcinoma 30.9 TP53 PTGS2 MKI67 KRT20 EGFR CDH1
37 peripheral nervous system disease 30.9 TP53 PTGS2 ERBB2 EGFR CDH1
38 interstitial cystitis 30.9 UPK3A UPK2 UPK1B UPK1A
39 lynch syndrome 30.9 TP53 PTGS2 MSH2 KRT7 ERBB2 EGFR
40 penile cancer 30.8 TP53 EGFR CDH1
41 urethral diverticulum 30.8 UPK3A KRT7 KRT20
42 wilms tumor 1 30.8 TP53 KRT7 ERBB2 EGFR CDH1
43 mucinous adenocarcinoma 30.7 TP53 MSH2 KRT7 KRT20 ERBB2 EGFR
44 papillary serous adenocarcinoma 30.7 TP53 KRT7 ERBB2
45 papillary adenocarcinoma 30.7 TP53 KRT7 ERBB2
46 vulval paget's disease 30.7 UPK3A KRT7 ERBB2
47 cervix carcinoma 30.7 TP53 KRT7 FGFR3 ERBB2 EGFR CDH1
48 urethral benign neoplasm 30.7 TP53 KRT7 KRT20
49 rectum cancer 30.7 TP53 MSH2 KRT20 EGFR
50 endometrial cancer 30.7 TP53 PTGS2 MSH2 MKI67 KRT7 KRT20

Graphical network of the top 20 diseases related to Transitional Cell Carcinoma:



Diseases related to Transitional Cell Carcinoma

Symptoms & Phenotypes for Transitional Cell Carcinoma

GenomeRNAi Phenotypes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.15 BRINP1 CDH1 EGFR ERBB2 FGFR3 IFNA2
2 no effect GR00402-S-2 10.15 BRINP1 EGFR ERBB2 FGFR3 IFNA2 KRT18

MGI Mouse Phenotypes related to Transitional Cell Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.2 CDH1 EGFR ERBB2 FGFR3 KRT18 MKI67
2 homeostasis/metabolism MP:0005376 10.2 BRINP1 CDH1 EGFR ERBB2 FGFR3 KRT7
3 normal MP:0002873 10.17 CDH1 EGFR ERBB2 FGFR3 IFNA2 MKI67
4 no phenotypic analysis MP:0003012 10.01 BRINP1 CDH1 EGFR FGFR3 MKI67 PTGS2
5 renal/urinary system MP:0005367 9.97 EGFR FGFR3 KRT7 PTGS2 TP53 TP63
6 cellular MP:0005384 9.93 BRINP1 CDH1 EGFR ERBB2 FGFR3 KRT18
7 digestive/alimentary MP:0005381 9.86 CDH1 EGFR ERBB2 FGFR3 MSH2 PTGS2
8 immune system MP:0005387 9.73 CDH1 EGFR FGFR3 IFNA2 KRT18 MKI67
9 integument MP:0010771 9.28 CDH1 EGFR ERBB2 FGFR3 MSH2 PSCA

Drugs & Therapeutics for Transitional Cell Carcinoma

Drugs for Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
2 Calciferol Phase 4
3
Ramucirumab Approved, Investigational Phase 3 947687-13-0
4
Aminolevulinic acid Approved Phase 3 106-60-5 137
5
Panitumumab Approved, Investigational Phase 3 339177-26-3
6
Avelumab Approved, Investigational Phase 3 1537032-82-8
7
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60699 60700
8
Infigratinib Approved, Investigational Phase 3 872511-34-7 53235510
9
Pembrolizumab Approved Phase 2, Phase 3 1374853-91-4 254741536
10
Lenvatinib Approved, Investigational Phase 2, Phase 3 417716-92-8 9823820
11
BCG vaccine Approved, Investigational Phase 3
12
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
13
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
14
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1, 93107-08-5 2764
15
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
16
Valrubicin Approved Phase 3 56124-62-0 41744
17
Laevulinic Acid Experimental Phase 3 123-76-2 11579
18
Cediranib Investigational Phase 3 288383-20-0 9933475
19
Maleic acid Experimental, Investigational Phase 3 110-16-7, 110-17-8 444266 444972
20
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
21 Carotenoids Phase 3
22 Hematinics Phase 3
23 BB 1101 Phase 3
24 Photosensitizing Agents Phase 3
25 topoisomerase I inhibitors Phase 2, Phase 3
26 Taxane Phase 3 108169
27 Anesthetics Phase 3
28 Antineoplastic Agents, Immunological Phase 2, Phase 3
29 Immune Checkpoint Inhibitors Phase 2, Phase 3
30 Liver Extracts Phase 2, Phase 3
31 Protein Kinase Inhibitors Phase 3
32 Adjuvants, Immunologic Phase 3
33 Fluoroquinolones Phase 3
34 Cytochrome P-450 Enzyme Inhibitors Phase 3
35 interferons Phase 2, Phase 3
36
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
37
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
38
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
39
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
40
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
41
Hydroxocobalamin Approved Phase 2 13422-51-0 15589840 44475014
42
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
43
Mecobalamin Approved, Investigational Phase 2 13422-55-4
44
Raloxifene Approved, Investigational Phase 2 82640-04-8, 84449-90-1 5035
45
Tamoxifen Approved Phase 2 10540-29-1, 54965-24-1 2733526
46
Ifosfamide Approved Phase 2 3778-73-2 3690
47
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
48
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
49
Epirubicin Approved Phase 2 56420-45-2 41867
50
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740

Interventional clinical trials:

(show top 50) (show all 546)
# Name Status NCT ID Phase Drugs
1 Pilot Study of the Biological Effects of Vitamin D in Patients With Resectable Urinary Tract Urothelial Carcinoma Completed NCT04197089 Phase 4 Vitamin D
2 A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma Not yet recruiting NCT05488353 Phase 4 Disitamab Vedotin for Injection,Penpulimab Injection
3 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
4 A Randomised Phase II/III Study of Cabazitaxel Versus Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium Unknown status NCT01830231 Phase 2, Phase 3 Cabazitaxel;Vinflunine
5 Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study Unknown status NCT00146276 Phase 3 gemcitabine
6 Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study - Unknown status NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
7 A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer Unknown status NCT01993979 Phase 3 Chemotherapy
8 A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression Unknown status NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
9 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00951496 Phase 3 Carboplatin;Cisplatin;Paclitaxel
10 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
11 Randomised Trial of Selective Bladder Preservation Against Radical Excision (Cystectomy) in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder - Feasibility Study Completed NCT00867347 Phase 3
12 A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy Completed NCT00389155 Phase 2, Phase 3 Vinflunine;Gemcitabine
13 Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy. Completed NCT01668459 Phase 2, Phase 3 Cabazitaxel
14 Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients With pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder Completed NCT00028756 Phase 3 doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
15 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma Completed NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
16 Prospective, Randomized Phase III Trial of I.V. Vinflunine Plus Best Supportive Care as Second Line Therapy Versus Best Supportive Care After a Platinum-containing Regimen, in Patients With Advanced Transitional Cell Carcinoma of Urothelial Tract Completed NCT00315237 Phase 3 vinflunine and best supportive care
17 A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
18 Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
19 Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder Completed NCT00003623 Phase 3
20 A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of UGN-101 on Ablation of Upper Urinary Tract Urothelial Carcinoma Completed NCT02793128 Phase 3 UGN-101 instillations
21 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
22 A Randomised Trial of Radical Chemo/Radiotherapy vs Radiotherapy Alone in the Definitive Management of Localised Muscle Invasive TCC of the Urinary Bladder Completed NCT00330499 Phase 3 Cisplatin
23 A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy Completed NCT03410693 Phase 2, Phase 3 Rogaratinib (BAY1163877);Chemotherapy
24 Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
25 A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) Completed NCT03374488 Phase 3 Pembrolizumab;Epacadostat;Placebo
26 Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
27 Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
28 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy Completed NCT02426125 Phase 3 Ramucirumab;Docetaxel;Placebo
29 A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) Completed NCT03361865 Phase 3 Pembrolizumab;Epacadostat;Placebo
30 Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study Completed NCT02818725 Phase 3 Chemotherapy;Panitumumab
31 A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma Completed NCT02853305 Phase 3 Cisplatin;Carboplatin;Gemcitabine
32 Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy Recruiting NCT04575935 Phase 3 Chemotherapy
33 Neoadjuvant Chemotherapy in Upper Tract Urothelial Cancer: A Multicentre, Feasibility Pilot Trial Recruiting NCT04574960 Phase 3 Gemcitabine;Cisplatin;Carboplatin
34 A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy Recruiting NCT04579224 Phase 3 Docetaxel;Eribulin Mesylate;Gemcitabine Hydrochloride;Paclitaxel
35 Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE) Recruiting NCT04637594 Phase 3 Pembrolizumab;Nivolumab;Atezolizumab;Durvalumab;Avelumab
36 A Phase 3b, Open-Label, Single-Arm, Multicenter Study to Assess the Feasibility of Home Instillation of UGN-102 for Treatment of Patients With Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence Recruiting NCT05136898 Phase 3 UGN-102
37 A Randomized Trial Comparing Intravesical Gemcitabine to Continuous Bladder Irrigation With Sterile Water to Prevent Bladder Cancer Implantation in Patients Undergoing Excision of Upper Tract Urothelial Carcinoma Recruiting NCT04865939 Phase 3 Gemcitabine
38 A Open-Label, Multicenter, Randomised, Controlled Phase 3 Study of RC48-ADC Plus Toripalimab Versus Chemotherapy Alone in Previously Untreated Unresectable Locally Advanced or Metastatic Urothelial Carcinoma With HER2-Expressing Recruiting NCT05302284 Phase 3 RC48-ADC;Toripalimab;Gemcitabine;Cisplatin;Carboplatin
39 A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence Recruiting NCT05243550 Phase 3 UGN-102
40 A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Either Cisplatin or Carboplatin +Gemcitabine + Tislelizumab Compared With Either Cisplatin or Carboplatin + Gemcitabine + Placebo as First-line Treatment for Patients With Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT03967977 Phase 3 Tislelizumab;Placebo;Cisplatin;Gemcitabine Hydrochloride;Carboplatin
41 MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer Recruiting NCT05092958 Phase 3 Avelumab;Cabozantinib S-malate
42 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
43 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
44 A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
45 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Active, not recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
46 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
47 A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011) Active, not recruiting NCT03898180 Phase 3 Lenvatinib;Placebo for lenvatinib
48 S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer Active, not recruiting NCT03091660 Phase 3
49 A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (LG IR NMIBC) Active, not recruiting NCT04688931 Phase 3 UGN-102
50 Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302) Active, not recruiting NCT04197986 Phase 3 Infigratinib;Placebo

Search NIH Clinical Center for Transitional Cell Carcinoma

Cochrane evidence based reviews: carcinoma, transitional cell

Genetic Tests for Transitional Cell Carcinoma

Anatomical Context for Transitional Cell Carcinoma

Organs/tissues related to Transitional Cell Carcinoma:

MalaCards : Lymph Node, Prostate, Kidney, Lung, Breast, Liver, T Cells

Publications for Transitional Cell Carcinoma

Articles related to Transitional Cell Carcinoma:

(show top 50) (show all 9616)
# Title Authors PMID Year
1
Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder. 53 62
20428812 2010
2
Sarcomatoid carcinoma of the urinary bladder: a case report with immunohistochemical and molecular genetic analysis. 53 62
19521796 2010
3
Isoenzyme profile of glutathione transferases in transitional cell carcinoma of upper urinary tract. 53 62
20403581 2010
4
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. 53 62
19888985 2010
5
p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. 53 62
20068172 2010
6
[Expressions of survivin and the splice variants survivin-2B and survivin-DeltaEx3 in bladder cancer and their clinical significance]. 53 62
19895744 2009
7
Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. 53 62
19443884 2009
8
Selection of optimal antisense accessible sites of uroplakin II mRNA for bladder urothelium. 53 62
19513619 2009
9
Sulforaphane down-regulates COX-2 expression by activating p38 and inhibiting NF-kappaB-DNA-binding activity in human bladder T24 cells. 53 62
19287971 2009
10
[Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder]. 53 62
19615282 2009
11
A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. 53 62
19115207 2009
12
Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer. 53 62
19186007 2009
13
Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract. 53 62
19473055 2009
14
Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study. 53 62
18367096 2008
15
Identification of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma. 53 62
19178674 2008
16
Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond. 53 62
18685414 2008
17
DNA polymorphisms in exon 1 and promoter of the CDH1 gene and relevant risk of transitional cell carcinoma of the urinary bladder. 53 62
18384629 2008
18
p63 expression in ovarian tumours: immunopositivity in metastatic transitional cell carcinoma of the ovary. 53 62
18518899 2008
19
Insights from a whole cystectomy specimen--association of primary small cell carcinoma of the bladder with transitional cell carcinoma in situ. 53 62
18547617 2008
20
RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. 53 62
18676844 2008
21
The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. 53 62
18430124 2008
22
Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. 53 62
18538698 2008
23
Differential accumulation of hypericin in spheroids composed of T-24 transitional cell carcinoma cells expressing different levels of E-cadherin. 53 62
18355860 2008
24
SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan. 53 62
18199464 2008
25
Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer. 53 62
18449376 2008
26
Survivin: a promising biomarker for detection and prognosis of bladder cancer. 53 62
17962949 2008
27
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. 53 62
17603559 2008
28
Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder. 53 62
18645275 2008
29
Downregulation of survivin is associated with reductions in TNF receptors' mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells. 53 62
18058462 2007
30
Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells. 53 62
18092951 2007
31
Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma. 53 62
17316722 2007
32
The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus. 53 62
17909029 2007
33
Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. 53 62
17826525 2007
34
Bacillus Calmette-Guérin induces p21 expression in human transitional carcinoma cell lines via an immediate early, p53 independent pathway. 53 62
17483019 2007
35
Cyclooxygenase-2 in transitional cell carcinoma--a legitimate target? 53 62
17296349 2007
36
Expression of p63 in thymomas and normal thymus. 53 62
17276940 2007
37
Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. 53 62
17296438 2007
38
Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. 53 62
17311305 2007
39
Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. 53 62
17222615 2007
40
Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. 53 62
17155984 2007
41
EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder. 53 62
17541304 2007
42
P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification. 53 62
18270948 2007
43
Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. 53 62
17987577 2007
44
Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. 53 62
16473461 2007
45
Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. 53 62
17133271 2006
46
Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. 53 62
16949911 2006
47
Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. 53 62
16984978 2006
48
Overexpression of PAX5 in oral carcinogenesis. 53 62
17016584 2006
49
The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. 53 62
17024120 2006
50
The role of glutathione transferases M1 and T1 in individual susceptibility to bladder cancer in a Tunisian population. 53 62
17381051 2006

Variations for Transitional Cell Carcinoma

Copy number variations for Transitional Cell Carcinoma from CNVD:

6 (show top 50) (show all 92)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 26136 1 197500000 205300000 Amplification LRRN2 Urothelial cell carcinoma
2 26141 1 197500000 205300000 Amplification MDM4 Urothelial cell carcinoma
3 26154 1 197500000 205300000 Loss Urothelial cell carcinoma
4 42679 10 3800000 6700000 Amplification PFKFB3 Urothelial cell carcinoma
5 49670 11 110000000 115400000 Loss ANKK1 Urothelial cell carcinoma
6 49671 11 110000000 115400000 Loss DRD2 Urothelial cell carcinoma
7 49672 11 110000000 115400000 Loss NCAM1 Urothelial cell carcinoma
8 49673 11 110000000 115400000 Loss TTC12 Urothelial cell carcinoma
9 52333 11 16100000 21600000 Loss PLEKHA7 Urothelial cell carcinoma
10 58688 11 69200000 70700000 Amplification CCND1 Urothelial cell carcinoma
11 58689 11 69200000 70700000 Amplification FGF19 Urothelial cell carcinoma
12 58690 11 69200000 70700000 Amplification FGF3 Urothelial cell carcinoma
13 58692 11 69200000 70700000 Amplification FGF4 Urothelial cell carcinoma
14 58694 11 69200000 70700000 Amplification LTO1 Urothelial cell carcinoma
15 58695 11 69200000 70700000 Amplification TPCN2 Urothelial cell carcinoma
16 58889 11 70700000 74900000 Amplification Urothelial cell carcinoma
17 58890 11 70700000 74900000 Amplification SHANK2-AS3 Urothelial cell carcinoma
18 58891 11 70700000 74900000 Amplification SHANK2 Urothelial cell carcinoma
19 64483 12 128700000 132349534 Loss FZD10 Urothelial cell carcinoma
20 69470 12 55200000 56300000 Amplification ARHGAP9 Urothelial cell carcinoma
21 69471 12 55200000 56300000 Amplification DCTN2 Urothelial cell carcinoma
22 69472 12 55200000 56300000 Amplification GLI1 Urothelial cell carcinoma
23 69473 12 55200000 56300000 Amplification INHBC Urothelial cell carcinoma
24 69474 12 55200000 56300000 Amplification KIF5A Urothelial cell carcinoma
25 69475 12 55200000 61400000 Amplification CDK4 Urothelial cell carcinoma
26 69476 12 55200000 61400000 Amplification METTL1 Urothelial cell carcinoma
27 69477 12 55200000 61400000 Amplification TSFM Urothelial cell carcinoma
28 69795 12 56300000 61400000 Amplification TAFA2 Urothelial cell carcinoma
29 69796 12 56300000 61400000 Amplification SLC16A7 Urothelial cell carcinoma
30 70900 12 66000000 69800000 Amplification CNOT2 Urothelial cell carcinoma
31 70901 12 66000000 69800000 Amplification CPM Urothelial cell carcinoma
32 70902 12 66000000 69800000 Amplification IFNG Urothelial cell carcinoma
33 70903 12 66000000 69800000 Amplification IL22 Urothelial cell carcinoma
34 70904 12 66000000 69800000 Amplification IL26 Urothelial cell carcinoma
35 70910 12 66000000 69800000 Amplification MDM2 Urothelial cell carcinoma
36 70911 12 66000000 69800000 Amplification TSPAN8 Urothelial cell carcinoma
37 71411 12 69800000 74100000 Amplification LGR5 Urothelial cell carcinoma
38 71412 12 69800000 74100000 Amplification THAP2 Urothelial cell carcinoma
39 71413 12 69800000 74100000 Amplification TMEM19 Urothelial cell carcinoma
40 71414 12 69800000 74100000 Amplification TPH2 Urothelial cell carcinoma
41 71668 12 74100000 78700000 Amplification NAV3 Urothelial cell carcinoma
42 72907 12 87500000 91200000 Amplification KITLG Urothelial cell carcinoma
43 73109 12 91200000 94800000 Amplification PLXNC1 Urothelial cell carcinoma
44 79797 13 77800000 86500000 Loss Urothelial cell carcinoma
45 94764 15 70400000 73100000 Loss NPTN Urothelial cell carcinoma
46 109762 17 28800000 35600000 Amplification ERBB2 Urothelial cell carcinoma
47 109763 17 28800000 35600000 Amplification TCAP Urothelial cell carcinoma
48 123109 18 66900000 71300000 Loss Urothelial cell carcinoma
49 123110 18 66900000 71300000 Loss TSHZ1 Urothelial cell carcinoma
50 123111 18 66900000 71300000 Loss PTGR3 Urothelial cell carcinoma

Expression for Transitional Cell Carcinoma

Search GEO for disease gene expression data for Transitional Cell Carcinoma.

Pathways for Transitional Cell Carcinoma

Pathways related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1 12.35 TP63 TP53 MSH2 MKI67
2
Show member pathways
12.32 TP53 PTGS2 MSH2 FGFR3 ERBB2 EGFR
3
Show member pathways
12.29 TP53 PTGS2 ERBB2 CDH1
4
Show member pathways
12.28 TP53 FGFR3 ERBB2 EGFR
5
Show member pathways
12.26 TP53 ERBB2 EGFR CDH1
6
Show member pathways
12.25 TP53 FGFR3 ERBB2 EGFR
7
Show member pathways
12.05 TP53 FGFR3 ERBB2 EGFR
8 11.91 CDH1 EGFR MSH2 TP53
9 11.87 TP53 PTGS2 MSH2 EGFR CDH1
10 11.85 TP53 FGFR3 ERBB2 EGFR
11 11.73 TP63 TP53 MSH2 EGFR
12 11.55 TP53 IFNA2 FGFR3
13 11.29 FGFR3 ERBB2 EGFR
14 11.22 TP63 TP53 FGFR3 ERBB2 EGFR
15 11.11 ERBB2 EGFR CDH1
16 10.7 UPK3A TP53 FGFR3 ERBB2 EGFR CDH1
17 10.52 PTGS2 EGFR
18 10.51 TP53 CDH1

GO Terms for Transitional Cell Carcinoma

Cellular components related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane urothelial plaque GO:0120001 9.1 UPK3A UPK1B UPK1A

Biological processes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.43 TP63 TP53 MSH2
2 epithelial cell differentiation GO:0030855 9.36 UPK3A UPK2 UPK1B UPK1A TP63 KRT20
3 positive regulation of miRNA maturation GO:1903800 9.16 TP53 EGFR

Molecular functions related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.1 FGFR3 ERBB2 EGFR

Sources for Transitional Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....